fingolimod hydrochloride has been researched along with Local Neoplasm Recurrence in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 5 (83.33) | 2.80 |
| Authors | Studies |
|---|---|
| Gębka-Kępińska, B; Sowa, P; Zięba, N | 1 |
| Alroughani, R; Barnett, M; Boz, C; Butler, E; Butzkueven, H; Buzzard, K; Duquette, P; Eichau, S; Garber, J; Gerlach, O; Girard, M; Grammond, P; Grand'Maison, F; Hodgkinson, S; Horakova, D; Izquierdo, G; Jokubaitis, V; Kalincik, T; Kermode, AG; Khoury, SJ; Kuhle, J; Laureys, G; Lechner-Scott, J; Macdonell, RAL; Merlo, D; Monif, M; Ozakbas, S; Patti, F; Prat, A; Prevost, J; Sa, MJ; Skibina, O; Slee, M; Terzi, M; van der Walt, A; Van Hijfte, L; Van Pesch, V; Van Wijmeersch, B; Weinstock-Guttman, B; Yamout, B; Zhou, Z; Zhu, C | 1 |
| Hsieh, TY; Lin, JC; Lu, MC; Shih, YL | 1 |
| Chen, HH; Chen, PL; Huang, CC; Huang, WN; Lee, WJ; Lin, CC; Lin, TS; Lyu, RK; Ro, LS; Su, JJ; Tsai, CP; Tsai, NW; Yang, A; Yang, CC | 1 |
| Berger, E; Bigaut, K; Brassat, D; Brochet, B; Bucciarelli, F; Cappé, C; Carra, C; Cohen, M; De Seze, J; Debouverie, M; Defer, G; Derache, N; Labauge, P; Laplaud, DA; Lebrun-Frenay, C; Mathey, G; Mondot, L; Pignolet, B; Ruet, A; Vermersch, P; Wiertlewski, S; Zephir, H | 1 |
| Borriello, L; Cherryholmes, G; DeClerck, YA; Lee, H; Li, W; Lifshitz, V; Makovski-Silverstein, A; Priceman, SJ; Yu, H | 1 |
1 review(s) available for fingolimod hydrochloride and Local Neoplasm Recurrence
| Article | Year |
|---|---|
BASAL CELL CARCINOMA AND SQUAMOUS CELL CARCINOMA IN A PATIENT TREATED WITH FINGOLIMOD FOR MULTIPLE SCLEROSIS - A CASE REPORT AND LITERATURE REVIEW.
Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasm Recurrence, Local; Skin Neoplasms | 2022 |
5 other study(ies) available for fingolimod hydrochloride and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.
Topics: Adult; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neoplasm Recurrence, Local; Recurrence | 2023 |
Flare of hepatitis B virus after fingolimod treatment for relapsing and remitting multiple sclerosis.
Topics: Cost-Benefit Analysis; Fingolimod Hydrochloride; Hepatitis B virus; Humans; Immunosuppressive Agents; Lymphoma; Multiple Sclerosis; Neoplasm Recurrence, Local | 2020 |
Real-world evidence on the safety and effectiveness of fingolimod in patients with multiple sclerosis from Taiwan.
Topics: Adult; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Neoplasm Recurrence, Local; Retrospective Studies; Taiwan | 2021 |
BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS.
Topics: Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Natalizumab; Neoplasm Recurrence, Local; Prospective Studies | 2021 |
Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance.
Topics: Animals; Apoptosis; Bone Marrow Cells; Drug Resistance, Neoplasm; Etoposide; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Gene-Environment Interaction; Humans; Mesenchymal Stem Cells; Mice; Neoplasm Recurrence, Local; Neuroblastoma; Receptors, Lysosphingolipid; RNA, Small Interfering; Sphingosine-1-Phosphate Receptors; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2017 |